Physician profile
David Scott Smith
NPI 1164443552
$8,412.97
in general payments reported to CMS, 2019-2025
33 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,852 · 2020: $489 · 2021: $663 · 2022: $1,209 · 2023: $1,608 · 2024: $1,110 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,156 · Debt Forgiveness: $43.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,156.40 |
| Debt Forgiveness | $43.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,893.95 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $885.87 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $677.53 | 2022-2025 | |
| Gilead Sciences, INC. | $589.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $577.50 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $430.09 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $300.78 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $264.43 | 2020-2025 | Givlaari |
| Ferring Pharmaceuticals INC. | $237.27 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $221.87 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $136.73 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $125.17 | 2023 | Ibsrela |
| Lilly USA, LLC | $115.08 | 2024-2025 | Omvoh |
| Echosens North America, INC. | $114.76 | 2019 | |
| Intercept Pharmaceuticals, INC. | $105.21 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $103.88 | 2019-2024 | Linzess |
| Boston Scientific Corporation | $98.89 | 2019 | |
| Intuitive Surgical, INC. | $94.72 | 2023 | Da Vinci Surgical System |
| Phathom Pharmaceuticals, INC. | $73.69 | 2024-2025 | Voquezna |
| Celgene Corporation | $46.61 | 2022-2024 | Zeposia |
| Baxter Healthcare | $43.93 | 2023 | |
| Merck Sharp & Dohme LLC | $42.11 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $33.68 | 2020-2021 | |
| Redhill Biopharma INC. | $33.45 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Olympus America INC. | $30.28 | 2025 | Olympus |
| Amarin Pharma, INC. | $27.75 | 2019 | |
| Madrigal Pharmaceuticals | $23.48 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $20.29 | 2025 | Zenpep |
| Shire North American Group INC | $17.45 | 2019 | |
| Novo Nordisk INC | $17.32 | 2025 | Wegovy |
| Dova Pharmaceuticals | $16.05 | 2019 | |
| W. L. Gore & Associates, INC. | $14.14 | 2023 | Gore Cardioform Septal Occluder |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.